AbbVie
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial
July 12, 2018Research and Development AbbVie, Cancer, FDA, Janssen, approval
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …
Syntimmune appoints Pfizer, AbbVie veteran as new CMO
July 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune
The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …
Top Ten most popular articles on Pharmafile.com this week
July 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Astrazenaca, Donald Trump, Pfizer, pharma, top ten
As the first week of July comes to an end we take a look over the most popular stories of …
AbbVie ordered to pay $448m over generic delays
July 2, 2018Sales and Marketing AbbVie, FTC, androgel, besins, branded generics, pharma
A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham …
Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn
June 27, 2018Research and Development, Sales and Marketing AbbVie, Cancer, Goggle, calico, pharma
The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development …
AbbVie/Roche gain FDA approval for blockbuster treatment
June 11, 2018Sales and Marketing AbbVie, Roche, biotech, drugs, pharma, pharmaceutical
AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination …
Top Ten most popular articles on Pharmafile.com this week
April 13, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten
It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …
New hepatitis C combo boasts 97% cure rate for just $300
April 12, 2018Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi
A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …
AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3
April 11, 2018Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib
AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …
Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar
April 6, 2018Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma
Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …
Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack
March 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma
Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …
Ablynx’s vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus
March 26, 2018Research and Development, Sales and Marketing AbbVie, Ablynx, Sanofi, Vobarilizumab, pharma, systemic lupus erythematosus
Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …
AbbVie secures further strong results for potential blockbuster
March 13, 2018Research and Development AbbVie, biotech, drugs, elagolix, pharma, pharmaceutical
AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids …
Top Ten most popular articles on Pharmafile.com this week
March 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta
After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
